Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
Logo Image
|Articles|October 21, 2011

ICON Selected by the Biomarkers Consortium of the FNIH to Support Study Evaluating Variability in Insulin Secretory Parameters

ICON announced it has received a contract award from the Foundation for the National Institutes of Health (FNIH) to provide clinical support for the Biomarkers Consortium study entitled Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects.

ICON's metabolic research team will support the clinical execution of this project, including subject recruitment and testing in ICON's Clinical Pharmacology Unit, located in San Antonio, Texas.

The Biomarkers Consortium study aims to develop biomarkers that predict long-term beta cell function, particularly in response to an intervention or a new therapy for diabetes. Currently there is no accepted gold standard testing regimen for estimating beta cell function and many accepted regimens are technically complex, making them unsuitable for large, multi-center clinical studies. The study is one of a series

Related to this article

View more
Where AI Leads in Trial Design—and Where Humans Still Need To
Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.
Read more